CGT CDMO is a contract service provider specializing in cell and gene therapy development and manufacturing. These organizations focus on supporting product development in the field of cell and gene therapies by pharmaceutical companies, biotechnology companies and research institutions.
The global market for CGT CDMO was estimated to be worth US$ 3947.8 million in 2023 and is forecast to a readjusted size of US$ 16970 million by 2030 with a CAGR of 24.1% during the forecast period 2024-2030
Global key players of CGT CDMO include Catalent, Lonza and Thermo Fisher, etc. The top three players hold a share over 60%. North America is the largest market, has a share about 50%. In terms of product type, Immune Cells is the largest segment, occupied for a share of about 47%, and in terms of application, Pharmaceutical and Biotechnology Companies has a share about 82 percent.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CGT CDMO, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of CGT CDMO by region & country, by Type, and by Application.
The CGT CDMO market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CGT CDMO.
Market Segmentation
By Company
Catalent
Lonza
Thermo Fisher
ACG Biologics
WuXi AppTec
Charles River
Oxford Biomedica (OXB)
Novartis
OBiO
GenScript
Pharmaron
Porton
Segment by Type:
Immune Cells
Stem Cells
Viral Vectors
Plasmid DNA
Segment by Application
Pharmaceutical and Biotechnology Companies
Research and Academic Institutions
Hospital
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of CGT CDMO manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of CGT CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of CGT CDMO in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 CGT CDMO Product Introduction
1.2 Global CGT CDMO Market Size Forecast
1.3 CGT CDMO Market Trends & Drivers
1.3.1 CGT CDMO Industry Trends
1.3.2 CGT CDMO Market Drivers & Opportunity
1.3.3 CGT CDMO Market Challenges
1.3.4 CGT CDMO Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global CGT CDMO Players Revenue Ranking (2023)
2.2 Global CGT CDMO Revenue by Company (2019-2024)
2.3 Key Companies CGT CDMO Manufacturing Base Distribution and Headquarters
2.4 Key Companies CGT CDMO Product Offered
2.5 Key Companies Time to Begin Mass Production of CGT CDMO
2.6 CGT CDMO Market Competitive Analysis
2.6.1 CGT CDMO Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by CGT CDMO Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CGT CDMO as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Immune Cells
3.1.2 Stem Cells
3.1.3 Viral Vectors
3.1.4 Plasmid DNA
3.2 Global CGT CDMO Sales Value by Type
3.2.1 Global CGT CDMO Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global CGT CDMO Sales Value, by Type (2019-2030)
3.2.3 Global CGT CDMO Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Pharmaceutical and Biotechnology Companies
4.1.2 Research and Academic Institutions
4.1.3 Hospital
4.1.4 Others
4.2 Global CGT CDMO Sales Value by Application
4.2.1 Global CGT CDMO Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global CGT CDMO Sales Value, by Application (2019-2030)
4.2.3 Global CGT CDMO Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global CGT CDMO Sales Value by Region
5.1.1 Global CGT CDMO Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global CGT CDMO Sales Value by Region (2019-2024)
5.1.3 Global CGT CDMO Sales Value by Region (2025-2030)
5.1.4 Global CGT CDMO Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America CGT CDMO Sales Value, 2019-2030
5.2.2 North America CGT CDMO Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe CGT CDMO Sales Value, 2019-2030
5.3.2 Europe CGT CDMO Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific CGT CDMO Sales Value, 2019-2030
5.4.2 Asia Pacific CGT CDMO Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America CGT CDMO Sales Value, 2019-2030
5.5.2 South America CGT CDMO Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa CGT CDMO Sales Value, 2019-2030
5.6.2 Middle East & Africa CGT CDMO Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions CGT CDMO Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions CGT CDMO Sales Value
6.3 United States
6.3.1 United States CGT CDMO Sales Value, 2019-2030
6.3.2 United States CGT CDMO Sales Value by Type (%), 2023 VS 2030
6.3.3 United States CGT CDMO Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe CGT CDMO Sales Value, 2019-2030
6.4.2 Europe CGT CDMO Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe CGT CDMO Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China CGT CDMO Sales Value, 2019-2030
6.5.2 China CGT CDMO Sales Value by Type (%), 2023 VS 2030
6.5.3 China CGT CDMO Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan CGT CDMO Sales Value, 2019-2030
6.6.2 Japan CGT CDMO Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan CGT CDMO Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea CGT CDMO Sales Value, 2019-2030
6.7.2 South Korea CGT CDMO Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea CGT CDMO Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia CGT CDMO Sales Value, 2019-2030
6.8.2 Southeast Asia CGT CDMO Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia CGT CDMO Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India CGT CDMO Sales Value, 2019-2030
6.9.2 India CGT CDMO Sales Value by Type (%), 2023 VS 2030
6.9.3 India CGT CDMO Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Catalent
7.1.1 Catalent Profile
7.1.2 Catalent Main Business
7.1.3 Catalent CGT CDMO Products, Services and Solutions
7.1.4 Catalent CGT CDMO Revenue (US$ Million) & (2019-2024)
7.1.5 Catalent Recent Developments
7.2 Lonza
7.2.1 Lonza Profile
7.2.2 Lonza Main Business
7.2.3 Lonza CGT CDMO Products, Services and Solutions
7.2.4 Lonza CGT CDMO Revenue (US$ Million) & (2019-2024)
7.2.5 Lonza Recent Developments
7.3 Thermo Fisher
7.3.1 Thermo Fisher Profile
7.3.2 Thermo Fisher Main Business
7.3.3 Thermo Fisher CGT CDMO Products, Services and Solutions
7.3.4 Thermo Fisher CGT CDMO Revenue (US$ Million) & (2019-2024)
7.3.5 ACG Biologics Recent Developments
7.4 ACG Biologics
7.4.1 ACG Biologics Profile
7.4.2 ACG Biologics Main Business
7.4.3 ACG Biologics CGT CDMO Products, Services and Solutions
7.4.4 ACG Biologics CGT CDMO Revenue (US$ Million) & (2019-2024)
7.4.5 ACG Biologics Recent Developments
7.5 WuXi AppTec
7.5.1 WuXi AppTec Profile
7.5.2 WuXi AppTec Main Business
7.5.3 WuXi AppTec CGT CDMO Products, Services and Solutions
7.5.4 WuXi AppTec CGT CDMO Revenue (US$ Million) & (2019-2024)
7.5.5 WuXi AppTec Recent Developments
7.6 Charles River
7.6.1 Charles River Profile
7.6.2 Charles River Main Business
7.6.3 Charles River CGT CDMO Products, Services and Solutions
7.6.4 Charles River CGT CDMO Revenue (US$ Million) & (2019-2024)
7.6.5 Charles River Recent Developments
7.7 Oxford Biomedica (OXB)
7.7.1 Oxford Biomedica (OXB) Profile
7.7.2 Oxford Biomedica (OXB) Main Business
7.7.3 Oxford Biomedica (OXB) CGT CDMO Products, Services and Solutions
7.7.4 Oxford Biomedica (OXB) CGT CDMO Revenue (US$ Million) & (2019-2024)
7.7.5 Oxford Biomedica (OXB) Recent Developments
7.8 Novartis
7.8.1 Novartis Profile
7.8.2 Novartis Main Business
7.8.3 Novartis CGT CDMO Products, Services and Solutions
7.8.4 Novartis CGT CDMO Revenue (US$ Million) & (2019-2024)
7.8.5 Novartis Recent Developments
7.9 OBiO
7.9.1 OBiO Profile
7.9.2 OBiO Main Business
7.9.3 OBiO CGT CDMO Products, Services and Solutions
7.9.4 OBiO CGT CDMO Revenue (US$ Million) & (2019-2024)
7.9.5 OBiO Recent Developments
7.10 GenScript
7.10.1 GenScript Profile
7.10.2 GenScript Main Business
7.10.3 GenScript CGT CDMO Products, Services and Solutions
7.10.4 GenScript CGT CDMO Revenue (US$ Million) & (2019-2024)
7.10.5 GenScript Recent Developments
7.11 Pharmaron
7.11.1 Pharmaron Profile
7.11.2 Pharmaron Main Business
7.11.3 Pharmaron CGT CDMO Products, Services and Solutions
7.11.4 Pharmaron CGT CDMO Revenue (US$ Million) & (2019-2024)
7.11.5 Pharmaron Recent Developments
7.12 Porton
7.12.1 Porton Profile
7.12.2 Porton Main Business
7.12.3 Porton CGT CDMO Products, Services and Solutions
7.12.4 Porton CGT CDMO Revenue (US$ Million) & (2019-2024)
7.12.5 Porton Recent Developments
8 Industry Chain Analysis
8.1 CGT CDMO Industrial Chain
8.2 CGT CDMO Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 CGT CDMO Sales Model
8.5.2 Sales Channel
8.5.3 CGT CDMO Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Catalent
Lonza
Thermo Fisher
ACG Biologics
WuXi AppTec
Charles River
Oxford Biomedica (OXB)
Novartis
OBiO
GenScript
Pharmaron
Porton
*If Applicable.